Application of methyl brevifolincarboxylate in preparation of anti-influenza virus medicines

Application of methyl brevifolincarboxylate in preparation of anti-influenza virus medicines is disclosed. Through experiments, the inventors found that the methyl brevifolincarboxylate shows high resisting function against influenza A virus H1N1 subtype in a range of 0.78-100 [mu]g/mL and has an IC value of 18.90 +/- 5.65 [mu]mol/L that is relatively lower than the IC value ( 0.56 +/- 1.10 [mu]mol/L) of a contrast medicine that is ribavirin. Plaque experiment results show that the methyl brevifolincarboxylate can suppress, in a concentration-dependant manner, MDCK cell (Madin-Darby canine kidney cell) plaques caused by H1N1 viruses. The methyl brevifolincarboxylate can suppress expression of virus NP protein and PB2 polymerase in MDCK cells, and the suppressing function increasesalong with increase of the concentration. The methyl brevifolincarboxylate can suppress H3N2, with the IC value being 71.74 +/- 1.48 [mu]g/mL. 本发明公开了短叶苏木酚酸甲酯在制备抗流感病毒药物中的应用。发明人通过实验发现，短叶苏木酚酸甲酯在0.78-100μg/mL范围内表现出较强的抗抗甲型流感病毒H1N1亚型作用，其IC